WO2006051374A3 - Arylpiperazines useful as adrenergic receptor antagonists - Google Patents

Arylpiperazines useful as adrenergic receptor antagonists Download PDF

Info

Publication number
WO2006051374A3
WO2006051374A3 PCT/IB2005/003295 IB2005003295W WO2006051374A3 WO 2006051374 A3 WO2006051374 A3 WO 2006051374A3 IB 2005003295 W IB2005003295 W IB 2005003295W WO 2006051374 A3 WO2006051374 A3 WO 2006051374A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
receptor antagonists
adrenergic receptor
bph
treat
Prior art date
Application number
PCT/IB2005/003295
Other languages
French (fr)
Other versions
WO2006051374A2 (en
Inventor
Mohammad Salman
Nitya Anand
Gyan Chand Yadav
Somesh Sharma
Gobind Singh Kapkoti
Anita Chugh
Kamna Nanda
Original Assignee
Ranbaxy Lab Ltd
Mohammad Salman
Nitya Anand
Gyan Chand Yadav
Somesh Sharma
Gobind Singh Kapkoti
Anita Chugh
Kamna Nanda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Mohammad Salman, Nitya Anand, Gyan Chand Yadav, Somesh Sharma, Gobind Singh Kapkoti, Anita Chugh, Kamna Nanda filed Critical Ranbaxy Lab Ltd
Publication of WO2006051374A2 publication Critical patent/WO2006051374A2/en
Publication of WO2006051374A3 publication Critical patent/WO2006051374A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I), wherein A can be Formula (II), (III) or (IV), as α1a and/or α1d adrenergic receptor antagonists, which can be used to treat a disease or disorder mediated through α1a and/or α1d adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.
PCT/IB2005/003295 2004-11-11 2005-11-04 Arylpiperazines useful as adrenergic receptor antagonists WO2006051374A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2246DE2004 2004-11-11
IN2246/DEL/2004 2004-11-11

Publications (2)

Publication Number Publication Date
WO2006051374A2 WO2006051374A2 (en) 2006-05-18
WO2006051374A3 true WO2006051374A3 (en) 2006-07-06

Family

ID=35589654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003295 WO2006051374A2 (en) 2004-11-11 2005-11-04 Arylpiperazines useful as adrenergic receptor antagonists

Country Status (1)

Country Link
WO (1) WO2006051374A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092710A1 (en) * 2005-03-02 2006-09-08 Ranbaxy Laboratories Limited Metabolites of 2-{3-[4-(2-isopropoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-1h-isoindole-1,3-(2h)-dione

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005206A1 (en) * 1998-07-21 2000-02-03 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
WO2002044151A1 (en) * 2000-11-30 2002-06-06 Ranbaxy Laboratories Limited 1,4-disubstituted piperazine derivatives useful as uro-selective $g(a)1-adrenoceptor blockers
WO2003084928A1 (en) * 2002-04-08 2003-10-16 Ranbaxy Laboratories Limited Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005206A1 (en) * 1998-07-21 2000-02-03 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
WO2002044151A1 (en) * 2000-11-30 2002-06-06 Ranbaxy Laboratories Limited 1,4-disubstituted piperazine derivatives useful as uro-selective $g(a)1-adrenoceptor blockers
WO2003084928A1 (en) * 2002-04-08 2003-10-16 Ranbaxy Laboratories Limited Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers

Also Published As

Publication number Publication date
WO2006051374A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006044504A8 (en) Cgrp receptor antagonists
WO2005072308A3 (en) Cgrp receptor antagonists
WO2006047196A3 (en) Cgrp receptor antagonists
DE602005020655D1 (en) Carboxamide-spirolactam CGRP Receptor Antagonists
WO2006099268A3 (en) Cgrp receptor antagonists
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
ATE484505T1 (en) 5-SULFANYLMETHYLÄ1,2,4ÜTRIAZOLÄ1,5-AUPYRIMIDINE- - OLDERIVATES AS CXCR2 ANTAGONISTS
WO2006044449A3 (en) Cgrp receptor antagonists
WO2007146349A3 (en) Cgrp receptor antagonists
DK1551803T3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
WO2006078554A3 (en) Cgrp receptor antagonists
WO2006035282A3 (en) Muscarinic receptor antagonists
WO2009020470A3 (en) Cgrp receptor antagonists
HK1141788A1 (en) Novel heterocyclic compounds as mglu5 antagonists
WO2009120652A3 (en) Monocyclic cgrp receptor antagonists
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
WO2005118537A3 (en) Arylpiperazine derivatives as adrenergic receptor antagonists
WO2007029078A3 (en) Succinimide and glutarimide derivatives as adrenergic receptor antagonists
WO2006051374A3 (en) Arylpiperazines useful as adrenergic receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05805373

Country of ref document: EP

Kind code of ref document: A2